eferences 37196 Zhang, L., Morgan, R.A., Beane, J.D. et al. (2015) Tumor-infiltrating
lymphocytes genetically engineered with an inducible gene encoding
interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer
Res., 21 (10), 2278–2288.
97 Michot, J.M., Bigenwald, C., Champiat, S. et al. (2016) Immune-related
adverse events with immune checkpoint blockade: a comprehensive review.
Eur. J. Cancer, 54 , 139–148.
98 Naidoo, J., Page, D.B., Li, B.T. et al. (2015) Toxicities of the anti-PD-1 and
anti-PD-L1 immune checkpoint antibodies. Ann. Oncol., 26 (12), mdv383.
99 Chen, Y.Y., Jensen, M.C., and Smolke, C.D. (2010) Genetic control of
mammalian T-cell proliferation with synthetic RNA regulatory systems.
Proc. Natl. Acad. Sci. U.S.A., 107 (19), 8531–8536.
100 Di Stasi, A., Tey, S.-K., Dotti, G. et al. (2011) Inducible apoptosis as a safety
switch for adoptive cell therapy. N. Engl. J. Med., 365 (18), 1673–1683.
101 Wilson, D.S. and Szostak, J.W. (1999) In vitro selection of functional nucleic
acids. Annu. Rev. Biochem., 68 (1), 611–647.
102 Bonini, C., Ferrari, G., Verzeletti, S. et al. (1997) HSV-TK gene transfer into
donor lymphocytes for control of allogeneic graft-versus-leukemia. Science,
276 (5319), 1719–1724.
103 Miller, W., Flynn, P., McCullough, J. et al. (1986) Cytomegalovirus infection
after bone marrow transplantation: an association with acute graft-v-host
disease. Blood, 67 (4), 1162–1167.
104 Straathof, K.C., Spencer, D.M., Sutton, R.E., and Rooney, C.M. (2003) Suicide
genes as safety switches in T lymphocytes. Cytotherapy, 5 (3), 227–230.
105 Straathof, K.C., Pulè, M.A., Yotnda, P. et al. (2005) An inducible caspase 9
safety switch for T-cell therapy. Blood, 105 (11), 4247–4254.
106 Hoyos, V., Savoldo, B., Quintarelli, C. et al. (2010) Engineering CD19-specific
T lymphocytes with interleukin-15 and a suicide gene to enhance their
anti-lymphoma/leukemia effects and safety. Leukemia, 24 (6), 1160–1170.
107 Porter, D.L., Levine, B.L., Kalos, M. et al. (2011) Chimeric antigen receptor-
modified T cells in chronic lymphoid leukemia. N. Engl. J. Med., 365 (8), 725–733.
108 Morgan, R.A., Yang, J.C., Kitano, M. et al. (2010) Case report of a serious
adverse event following the administration of T cells transduced with a
chimeric antigen receptor recognizing ERBB2. Mol. Ther., 18 (4), 843–851.
109 Kalos, M., Levine, B.L., Porter, D.L. et al. (2011) T cells with chimeric antigen
receptors have potent antitumor effects and can establish memory in patients
with advanced leukemia. Sci. Transl. Med., 3 (95), 95ra73.
110 Wei, P., Wong, W.W., Park, J.S. et al. (2012) Bacterial virulence proteins as tools to
rewire kinase pathways in yeast and immune cells. Naturr, 488 (7411), 384–388.
111 Rosenberg, S.A. (2014) Finding suitable targets is the major obstacle to cancer
gene therapy. Cancer Gene Ther., 21 (2), 45–47.
112 Hinrichs, C.S. and Restifo, N.P. (2013) Reassessing target antigens for adoptive
T-cell therapy. Nat. Biotechnol., 31 (11), 999–1008.
113 Ho, P., Ede, C., and Chen, Y.Y. (2017) Modularly constructed synthetic
granzyme B molecule enables interrogation of intracellular proteases for
targeted cytotoxicity. ACS Synth. Biol., 6 , 1484–1495.